Navigation Links
Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
Date:11/12/2012

TORONTO, ON, Nov. 12, 2012 The Ontario Genomics Institute (OGI), through its Pre-Commercialization Business Development Fund (PBDF), has invested in Toronto-based Tissue Regenerative Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions, such as arthritis, diabetes and Crohn's disease, to name a few. TRT will use this investment to conduct studies required to apply for approval to initiate human clinical trials.

MSCs are cells that can differentiate into musculoco-skeletal tissues such as bone, cartilage and muscle. Their ability to generate replacement tissues and affect cellular processes such as inflammation makes them an exciting potential therapy for a variety of conditions. Unlike other cells, MSCs can be used without the need for tissue matching and can be accumulated in large numbers. TRT has developed new methods to extract MSCs from umbilical cords, eliminating many of the challenges related to MSC harvesting from other tissue sources.

"Stem cell research is a promising area of biomedical research and it could have significant impact for people suffering from many conditions," said Mark Poznansky, President and CEO, OGI. "TRT is an excellent example of an Ontario company developing innovative therapies and translating research into potential clinical applications."

TRT is aiming to launch clinical trials to test these cells within the next two years. The PBDF funding from OGI will fund proteomic and transcriptomic analyses to further understand TRT's stem cells. These studies will provide valuable information needed for regulatory approval to conduct human clinical trials and further differentiate their product from those of competitors.

"We believe that these stem cells represent a unique and potent means of treating multiple debilitating diseases," said John Davies, CEO of TRT. "The OGI funding will enable us to demonstrate the utility of
'/>"/>

Contact: Christine Beyaert
cbeyaert@ontariogenomics.ca
416-673-6597
Ontario Genomics Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Sudden cardiac death in Ontario under age 40 - is exercise dangerous?
2. Male Ontario students show declines in fighting; females show elevated bullying and mental distress
3. 2 Scripps Research Institute scientists honored by American Chemical Society
4. Merck and Regenstrief Institute establish evidence-based care collaboration
5. Institute for Population Health Improvement releases buyers guide for health information exchange
6. Feinstein Institute researchers discover that bean used in Chinese food could protect against sepsis
7. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
8. Northeasterns Barnett Institute announces formation of leading analytics company, BioAnalytix, LLC
9. Penn Translational Medicine Institute to hold 7th Annual Symposium
10. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
11. Weizmann Institutes mathematical model may lead to safer chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... 20, 2014 With a mere 19 ... Crist made a brief fundraising stop at the ... , Fresh from a debate last night with his ... stage for the first seven minutes because Crist had ... described the incident in one word: "weird." , Before ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 hc1.com ... a secure cloud solution that enables healthcare organizations ... the ultimate healthcare-specific customer relationship management (“CRM”) solution. ... the unique needs of the healthcare industry, the ... for providers and patients by combining healthcare CRM, ...
Breaking Medicine News(10 mins):Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... who are pre-, perimenopausal with dense breasts benefit most, ... For some women, digital mammography is a better bet ... Women under the age 50 with dense breasts who ... digital mammograms, said study author Dr. Etta Pisano, the ...
... its most selective filter to keep it from clogging with ... St. Louis reveal in a new study. , Researchers ... more vulnerable to dysfunction and disease. , "We speculate ... the filter that can damage it," says senior author Andrey ...
... Xoft, Inc., developer of the,Axxent(R) Electronic ... in,radiation oncology and non-invasive neurosurgery solutions, announced ... agreement., Under the agreement, Elekta will ... Electronic Brachytherapy in the radiation oncology,market. This ...
... Denver Museum of Nature & Science Reveals Plans for New $8 Million ... Interactive Health Science Exhibition ... Jan. 29 Beginning in April 2009, residents and,visitors to the Denver ... their health in ways they have never experienced at a museum,-- or ...
... ... Compliance, and Lowers Costs, NEWARK and EAST BRUNSWICK, N.J., ... empirical,data demonstrating the effectiveness of the Patient Centered Medical Home,(PC-MH), ... their personal physicians and -- when appropriate -- the,patient,s family. ...
... the American Roentgen Ray Society to add more journals ... , BioMed Central, the open access publisher of peer-reviewed ... 4,200 images to the GoldMiner collection. The collection now ... GoldMiner speeds your search for radiology images by quickly ...
Cached Medicine News:Health News:Digital Mammography Better Than Film for Some Women 2Health News:Digital Mammography Better Than Film for Some Women 3Health News:Breakdown of kidney's ability to clean its own filters likely causes disease 2Health News:Breakdown of kidney's ability to clean its own filters likely causes disease 3Health News:Xoft Signs Sales Development Agreement With Elekta 2Health News:Xoft Signs Sales Development Agreement With Elekta 3Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 2Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 3Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 4Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 5Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 6Health News:Ground Breaking Program Improves Diabetes Patient Outcomes 2Health News:Ground Breaking Program Improves Diabetes Patient Outcomes 3
(Date:10/22/2014)... CITY, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced that results from the  IAP310 study ... Pain Medicine (RAPM), a peer-reviewed journal with ... Phase 3 trial evaluating the safety and efficacy ... sublingual tablet system (SSTS), for the treatment of ...
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( ... pulmonology, today announced completion of enrollment in their RENEW ... Clinical Study is the FDA-approved IDE pivotal trial for ... emphysema. It was anticipated that the study, ... 2013, would take until the end of 2014 to ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
Vertigraft femoral shaft an large femoral cross-section designed primarily for use in lumbar corpectomy procedures. Freeze dried preservation....
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... fiber reinforced polymer material emulates the biomechanical ...
... bone graft substitute (beta-tricalcium ... Chronos is an advantageous ... It shortens operative time, ... quantity and quality of ...
... bone regeneration scaffold. Its ... composite ensures ideal osteoconductivity, ... structure maximizes permeability even ... the most meaningful measure ...
Medicine Products: